Dulaglutide

Summary

Dulaglutide (CHEMBL2108027) is an approved protein (ATC A10BJ05); indicated across 6 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: A10BJ05
• Indications: 6 conditions
• Clinical trials: 106

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108027
Name	Dulaglutide
Type	Protein
Max phase	4
ATC	A10BJ05

Also known as: Dulaglutida, Dulaglutide, Dulaglutide component of trulicity, LY-2189265, LY2189265, Trulicity, DULAGLUTIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	4	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	4	MONDO:0005148	MONDO:0005148
chronic kidney disease	2	MONDO:0005300	EFO:0003884
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 106.

Phase distribution

Phase	Trials
PHASE3	31
PHASE1	22
PHASE2	21
PHASE4	16
Not specified	12
PHASE2/PHASE3	2
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06851962	PHASE4	ACTIVE_NOT_RECRUITING	Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
NCT07537088	PHASE4	NOT_YET_RECRUITING	Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
NCT02750410	PHASE4	COMPLETED	A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
NCT03315780	PHASE4	COMPLETED	A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes
NCT03444142	PHASE4	UNKNOWN	Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes
NCT03743025	PHASE4	TERMINATED	Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
NCT03824002	PHASE4	COMPLETED	Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
NCT04189848	PHASE4	COMPLETED	Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
NCT04387201	PHASE4	COMPLETED	GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
NCT04862234	PHASE4	TERMINATED	Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients
NCT04893148	PHASE4	UNKNOWN	Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes
NCT05005741	PHASE4	UNKNOWN	The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.
NCT05140694	PHASE4	UNKNOWN	Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
NCT05218915	PHASE4	COMPLETED	Basal Plus GLP1-ra on Glycemic Variability in CKD
NCT05564039	PHASE4	COMPLETED	A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
NCT05659537	PHASE4	COMPLETED	A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India
NCT06257966	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
NCT06739122	PHASE3	RECRUITING	A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT07156539	PHASE3	NOT_YET_RECRUITING	A Phase 3 Study of HS-20094 in Patients With T2DM
NCT07282041	PHASE2/PHASE3	RECRUITING	Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
NCT00734474	PHASE2/PHASE3	COMPLETED	A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
NCT01064687	PHASE3	COMPLETED	A Study in Participants With Type 2 Diabetes Mellitus
NCT01075282	PHASE3	COMPLETED	A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
NCT01126580	PHASE3	COMPLETED	A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
NCT01191268	PHASE3	COMPLETED	A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4)
NCT01394952	PHASE3	COMPLETED	Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
NCT01468181	PHASE3	COMPLETED	A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
NCT01558271	PHASE3	COMPLETED	A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
NCT01584232	PHASE3	COMPLETED	A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
NCT01621178	PHASE3	COMPLETED	A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
NCT01624259	PHASE3	COMPLETED	A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
NCT01644500	PHASE3	COMPLETED	A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
NCT01648582	PHASE3	COMPLETED	A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
NCT01769378	PHASE3	COMPLETED	Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)
NCT02152371	PHASE3	COMPLETED	A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
NCT02597049	PHASE3	COMPLETED	A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
NCT02648204	PHASE3	COMPLETED	Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
NCT02787551	PHASE3	COMPLETED	Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT02963766	PHASE3	COMPLETED	A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
NCT03015220	PHASE3	COMPLETED	Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).